RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Orchard Therapeutics Stock

Orchard Therapeutics Stocks 2024

Orchard Therapeutics Stocks

127.98 M

Ticker

ORTX

ISIN

US68570P1012

WKN

A2N8KD

In 2024, Orchard Therapeutics had 127.98 M outstanding stocks, a 0% change from the 127.98 M stocks in the previous year.

The Orchard Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2028e127.98
2027e127.98
2026e127.98
2025e127.98
2024e127.98
2023e127.98
2022127.98
2021123.96
20209.94
20199.32
20188.59
20178.31
20168.31

Orchard Therapeutics shares outstanding

The number of shares was Orchard Therapeutics in 2023 — This indicates how many shares 127.98 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Orchard Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Orchard Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Orchard Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Orchard Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Orchard Therapeutics Aktienanalyse

What does Orchard Therapeutics do?

Orchard Therapeutics PLC is a biopharmaceutical company based in London. It was founded in 2015 and is traded on the NASDAQ and the London Stock Exchange. The company focuses on the development and commercialization of gene therapy products for rare and life-threatening diseases for which there is currently no cure. Orchard Therapeutics has its roots in the research and development of gene therapy products at the University College London (UCL) and the Great Ormond Street Hospital for Children (GOSH). The company has a strong partnership with these institutions and utilizes their resources for the development of new therapies. This close collaboration allows Orchard Therapeutics to focus on the research and development of gene therapy products for rare diseases. The business model of Orchard Therapeutics is to develop gene therapies for rare diseases that currently have no treatment options. These products are then licensed to pharmaceutical companies that are responsible for the production and marketing of the products. Orchard Therapeutics then receives a licensing fee and potential milestone payments for the sale of the products. Orchard Therapeutics has various divisions specializing in the development of gene therapies for different diseases. For example, the hemophilia division develops gene therapies for people with hemophilia, a genetic disease that impairs blood clotting. Other divisions focus on the development of gene therapies for muscular dystrophy, B-cell immunodeficiency, and chronic granulomatosis. The company has a broad portfolio of products currently in development. One of the most well-known products is "OTL-101," a gene therapy for the treatment of adenosine deaminase deficiency immunodeficiency (ADA-SCID), a severe type of immunodeficiency that can lead to infections and serious illness. Another important gene therapy is "OTL-103," which is used for the treatment of Wiskott-Aldrich syndrome (WAS), a rare genetic disorder that affects the immune system. Orchard Therapeutics manages to develop gene therapies for rare diseases by using a unique technology platform. This platform includes the use of lentiviruses that can insert genetic information into cells of the body. The gene therapies developed on this platform can help replace defective or missing genes with functional genes to treat diseases. Overall, Orchard Therapeutics is an emerging biotechnology company that focuses on the development of gene therapy products for rare and life-threatening diseases. The company has a strong partnership with leading medical institutions and utilizes a unique technology platform to develop gene therapies. With a wide range of products in development and potential groundbreaking therapies in the pipeline, Orchard Therapeutics is expected to play a significant role in the development of gene therapies for rare diseases. Orchard Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Orchard Therapeutics's Shares Outstanding

Orchard Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Orchard Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Orchard Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Orchard Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Orchard Therapeutics stock

How many stocks are there of Orchard Therapeutics?

The current number of stocks of Orchard Therapeutics is 127.98 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Orchard Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Orchard Therapeutics evolved in recent years?

The number of shares of Orchard Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Orchard Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Orchard Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Orchard Therapeutics pay?

Over the past 12 months, Orchard Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Orchard Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Orchard Therapeutics?

The current dividend yield of Orchard Therapeutics is .

When does Orchard Therapeutics pay dividends?

Orchard Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Orchard Therapeutics?

Orchard Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Orchard Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Orchard Therapeutics located?

Orchard Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Orchard Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Orchard Therapeutics from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Orchard Therapeutics pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Orchard Therapeutics in the year 2023?

In the year 2023, Orchard Therapeutics distributed 0 USD as dividends.

In which currency does Orchard Therapeutics pay out the dividend?

The dividends of Orchard Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Orchard Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Orchard Therapeutics

Our stock analysis for Orchard Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Orchard Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.